NCT02083887View on ClinicalTrials.gov

A Phase I Study to Assess the Safety and Immunogenicity of ChAd63 ME-TRAP - MVA ME-TRAP Heterologous Prime-boost Vaccination Co-administered With EPI Vaccines in Gambian Infants

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Malaria
Interventions
BIOLOGICAL

ChAd63 ME-TRAP / MVA ME-TRAP

Intramuscular administration of ChAd63 ME-TRAP 5 x 10\^10 vp and MVA ME-TRAP 1 x 10\^8 pfu

Trial Locations (1)

PO Box 273

Medical Research Council Unit, Fajara, Banjul

All Listed Sponsors
collaborator

Malaria Vectored Vaccines Consortium

OTHER

lead

University of Oxford

OTHER

NCT02083887 - A Phase I Study to Assess the Safety and Immunogenicity of ChAd63 ME-TRAP - MVA ME-TRAP Heterologous Prime-boost Vaccination Co-administered With EPI Vaccines in Gambian Infants | Biotech Hunter | Biotech Hunter